Inhibiting FASN using orlistat can reverse acquired resistance to trastuzumab in breast and ovarian cancer cells [63,64], as well as hyper-sensitize breast cancer cells to doxorubicin, docetaxel, paclitaxel, or vinorelbine [65,66]. Here, FASN is linked to ovarian carcinoma.